Procarbazine Therapy for Hodgkin's Disease in Early Pregnancy
- James H. Wells, MD;
- John R. Marshall, MD;
- Paul P. Carbone, MD
Abstract
Procarbazine hydrochloride, an antineoplastic agent, a teratogen, and a carcinogen, was given to a patient with Hodgkin's disease during the first 5 1/2 weeks of her pregnancy, and a normal infant was delivered. Based on past experience with chemotherapeutic agents given to pregnant women with Hodgkin's disease, the authors present a program of management for the pregnant patient with Hodgkin's disease.
Footnotes
-
Reprint requests to National Cancer Institute, Bethesda. Md 20014 (Dr. Carbone).
